Vermont and Connecticut have recently signed laws providing a pathway for and regulations around the substitution of interchangeable biosimilars for the reference biologic product at the pharmacy level.
A number of states have recently been considering legislation around interchangeable biosimilar substitution at the pharmacy level. Vermont and Connecticut are among the 2 latest states to enact such regulation.
On May 30, 2018, Vermont Governor Phil Scott signed bill S.92 into law as Act No. 193. The Act instructs pharmacists to dispense the lowest-price interchangeable biological product to the patient, as well as notify the prescriber of which biological product has been dispensed.
Specifically, within 5 days of the biological product being dispensed, the pharmacist must communicate to the prescriber electronically through either an interoperable electronic medical records system, an electronic prescribing technology, a pharmacy benefit management system, or a pharmacy record.
In Connecticut, Governor Dannel Malloy signed S. Bill No. 197 into law as Public Act No. 18-74 on June 4, 2018. The Act allows a pharmacist to substitute an interchangeable biological product for a prescribed biological product if it provides a cost saving to the patient. In addition, the Act also includes provisions stipulating the notification to the patient purchasing the drug that there may be a cheaper interchangeable biological product available.
The Act also requires the dispensing physician to make an entry documenting the substitution, as well as inform the prescribing practitioner by facsimile, telephone, or electronic transmission of the substitution.
With the implementation of these laws, Vermont and Connecticut have joined 43 other states and Puerto Rico that have authorized legislation around the substitution of interchangeable biosimilars, despite the FDA having not approved such a product to date.
New Hampshire and Alaska are currently considering similar legislation.
BioRationality: MHRA's Procedure Enables Automatic Registration of Biosimilars Approved Elsewhere
March 18th 2024Sarfaraz K. Niazi, PhD, explains how the new international recognition procedure under the Medicines and Healthcare Products Regulatory Agency (MHRA) could expand biosimilar access within the United Kingdom, in his latest column.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
FDA Green Lights Second Tocilizumab Biosimilar
March 7th 2024The FDA has approved Fresenius Kabi's tocilizumab biosimilar (Tyenne; tocilizumab-aazg), making it the second tocilizumab biosimilar overall and first tocilizumab biosimilar to be approved with both intravenous and subcutaneous administration options.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
BioRationality: EMA Announces Readiness to Waive Comparative Efficacy Studies of Biosimilars
March 4th 2024Sarfaraz K. Niazi, PhD, takes a look at the European Medicines Agency's (EMA) announcement that it will investigate whether comparative efficacy tests should be needed for a biosimilar to receive regulatory approval.
Samsung Bioepis Announces New Biosimilar Partnership, Regulatory Updates
February 27th 2024Samsung Bioepis provided multiple updates on its biosimilar projects, including a new partnership for its aflibercept biosimilar candidate as well as regulatory news in the European Union and Republic of Korea.